Purilogics Debuts Manufacturing Grade Purexa™ Membrane Chromatography Technology to Support Customers' GMP Processes
Ready-to-use consumable enhances downstream productivity
Purilogics, a Donaldson Life Sciences business specializing in biopharmaceutical membrane chromatography development, today announced the availability of its first manufacturing-grade product within its Purexa™ portfolio—Purexa NAEX (Novel Anion Exchange) Prep membrane technology—to support customers' GMP processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730413521/en/
A novel weak anion-exchange membrane chromatography product, Purexa™ NAEX has high binding capacity with targeted molecules and is now available in manufacturing-grade.
The Purexa NAEX Prep is the first Purilogics product to become available in manufacturing grade. Specifically designed for the purification of supercoiled plasmid DNA (pDNA), the ready-to-use consumable offers easy setup and breakdown and is compatible with most chromatography systems. Manufacturing of the Purexa NAEX membrane technology takes places in an ISO 9001, Class 7 cleanroom certified facility with a quality system and process located in Bloomington, Minnesota, while R&D activities take place at the company's state-of-the-art innovation center in Greenville, South Carolina.
"We selected the Purexa NAEX membrane chromatography products for our initial expansion into manufacturing-grade offerings due to their broad applicability," said Jin Zhou, Director of Purilogics. "These products enhance downstream productivity in three key ways: (1) with high dynamic binding capacity, (2) fast cycle times and (3) in an efficient and scalable format. This allows users to process their product more quickly versus traditional chromatography columns, helping reduce process costs as well."
Additional research-grade and manufacturing-grade products within the Purexa membrane chromatography portfolio will be released throughout 2025 and 2026. The Purexa product portfolio also includes Purexa MCP membrane chromatography products for the polishing of supercoiled pDNA, Purexa OdT membrane chromatography products for mRNA purification, and Purexa PrA membrane chromatography products for capture step antibody purification. Each of the Purexa technologies will be available in a comprehensive range of membrane products including lab-scale "Plate" and "Prep" products, development-scale "Pilot" and large-scale manufacturing "Process" products.
For more information and to obtain a quote, please reach out to a member of the Purilogics team at [email protected] or at https://www.purilogics.com/contact. To stay up to date on the product journey for innovative membrane chromatography solutions, follow the company on LinkedIn at https://www.linkedin.com/company/purilogics-by-donaldson/.
About Purilogics by Donaldson
Purilogics, a Donaldson Life Sciences company, is a multi-modality biopharmaceutical membrane technology developer. The company's innovative membrane chromatography solutions significantly enhance the efficiency, speed and scalability of biologics purification. By integrating advanced materials and engineering, Purilogics provides products that meet the rigorous demands of modern biomanufacturing. The company offers tailored solutions for applications including nucleic acids, monoclonal antibodies, viral vectors and other therapeutic proteins, aiming to help biopharmaceutical companies achieve superior productivity, product purity and yield.
Incorporated in 2013, Purilogics became part of Donaldson Company (NYSE:DCI) in 2022.
For more information, visit www.purilogics.com.
About Donaldson Life Sciences – Bioprocessing
Long a pioneer in filtration solutions, Donaldson Company (NYSE:DCI) continues to expand into the Life Sciences sector. The Bioprocessing division is concentrated on developing solutions from R&D to commercialization for multi-modality drug manufacturers. The division was built via acquisitions of Isolere Bio for multi-modality reagents; Purilogics for bioprocessing membranes; and Solaris Biotech and Univercells Technologies for innovative production technologies. These teams are driven to continuously innovate, evolve, and deliver Smarter Bioprocessing solutions that help developers improve global health.
For more information, visit www.donaldsonlifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250730413521/en/
For more information, contact:
Gray Player (919) 699-5718
[email protected]